Studies of autoantibodies reactive with thyroid membrane antigens and insulin in non obese diabetic mice

The genetics of Hashimoto's disease

Despite strong epidemiologic evidence in favor of a genetic component in the etiology of HT, few hereditary risk factors have been consistently identified. These factors include the HLA and CTLA-4 genes. The mechanisms by which these genes confer increased susceptibility to HT are unclear. The identification of these genes has failed to explain completely the large hereditary effect observed in families of patients. More substantial genetic determinants must be hidden in the folds of the human genome and will most likely be detected in the near future. The powerful approach of linkage analysis will be supported by advancements in the description of the human genome and by technologic improvements in the ability to process large amounts of biologic data. Knowledge of such determinants will provide predictive tools to be used on clinical grounds and invaluable insight into the pathogenesis of this puzzling disease.

Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis

Development of type 1 insulin-dependent diabetes mellitus has been recently reported in patients who underwent interferon-alpha (IFN-alpha) therapy because of chronic viral hepatitis. Furthermore IFN-alpha seems to be involved in the immunological events that lead to beta-cell destruction and development of type 1 diabetes. To evaluate whether IFN-alpha treatment could elicit an autoimmune response against beta-cell antigens, we determined the occurrence of islet cell antibodies and insulin autoantibodies in the sera of 60 patients with HCV- or HBV-related chronic hepatitis who had been treated with IFN-alpha for 6 or 12 months. The presence of antibodies against thyroglobulin, thyroid microsomal antigen, gastric parietal cells, and non-organ-specific antigens was also investigated. Insulin autoantibody positivity was observed in 2/60 (3.3%), 8/60 (13.3%), and 4/30 (13.3%) patients, before IFN-alpha treatment, and after 6 months and 12 months of therapy, respectively. None of the studied patients developed islet cell antibodies or type 1 diabetes. Before IFN-alpha therapy four patients showed thyroid autoantibodies and four others developed antibodies against thyroglobulin and/or thyroid microsomal antigen during the treatment. Coexistence of insulin autoantibodies and thyroid autoantibodies was observed in only two patients. Our results showed that IFN-alpha therapy in patients with chronic viral hepatitis is capable of inducing development of autoantibodies against insulin. This event seems to be not related to other autoimmune disorders.